{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:28:27Z","timestamp":1786339707375,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00817-w","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:42:32Z","timestamp":1786336952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential therapy with decitabine and an XPO-1 inhibitor followed by allogeneic hematopoietic stem cell transplantation in MDS with biallelic TP53 inactivation patients : a preliminary case series"],"prefix":"10.1186","volume":"15","author":[{"given":"Yanling","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"7","key":"817_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","volume":"38","author":"C Bally","year":"2014","unstructured":"Bally C, Ades L, Renneville A, Sebert M, Eclache V, Preudhomme C, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014;38(7):751\u20135.","journal-title":"Leuk Res"},{"issue":"21","key":"817_CR2","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H Dohner","year":"2024","unstructured":"Dohner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024;144(21):2211\u201322.","journal-title":"Blood"},{"issue":"15","key":"817_CR3","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, et al. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023;41(15):2815\u201326.","journal-title":"J Clin Oncol"},{"issue":"1","key":"817_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40164-025-00678-9","volume":"14","author":"R Thalla","year":"2025","unstructured":"Thalla R, Mack R, Kosti-Schwartz J, Breslin P, Zhang J. Advances and challenges in the treatment of myelodysplastic syndromes. Exp Hematol Oncol. 2025;14(1):87.","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"817_CR5","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","volume":"9","author":"K Lontos","year":"2025","unstructured":"Lontos K, Saliba RM, Kanagal-Shamanna R, Ozcan G, Ramdial J, Chen G, et al. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation. Blood Adv. 2025;9(11):2845\u201354.","journal-title":"Blood Adv"},{"issue":"1","key":"817_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/hematology.2024000558","volume":"2024","author":"HF Fernandez","year":"2024","unstructured":"Fernandez HF, Mishra A. Transplant options and outcomes for TP53 myeloid disease. Hematol Am Soc Hematol Educ Program. 2024;2024(1):335\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"817_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40164-025-00652-5","volume":"14","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Lopez-Guerra M, Castano-Diez S, Esteban D, Avendano A, Pomares H, et al. Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study. Exp Hematol Oncol. 2025;14(1):61.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"817_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41409-024-02486-x","volume":"60","author":"B Jiang","year":"2025","unstructured":"Jiang B, Yang T, Zhao Y, Luo Y, Ouyang G, Yu J, et al. Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy? Bone Marrow Transpl. 2025;60(3):326\u201334.","journal-title":"Bone Marrow Transpl"},{"key":"817_CR9","doi-asserted-by":"crossref","unstructured":"Long H, Hou Y, Li J, Song C, Ge Z. Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1\/eIF4E\/c-MYC Signaling. Int J Mol Sci. 2023;24(7).","DOI":"10.3390\/ijms24076816"},{"issue":"4","key":"817_CR10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s10637-022-01251-5","volume":"40","author":"Y Guo","year":"2022","unstructured":"Guo Y, Liu Z, Duan L, Shen H, Ding K, Fu R. Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. Invest New Drugs. 2022;40(4):738\u201346.","journal-title":"Invest New Drugs"},{"issue":"8","key":"817_CR11","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3026(20)30209-X","volume":"7","author":"J Taylor","year":"2020","unstructured":"Taylor J, Mi X, Penson AV, Paffenholz SV, Alvarez K, Sigler A, et al. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2020;7(8):e566\u201374.","journal-title":"Lancet Haematol"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00817-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:42:44Z","timestamp":1786336964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00817-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00817-w","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board of The First Affiliated Hospital of Zhejiang University, School of Medicine (Approval No.: 0352-2026B). Although a waiver of informed consent was granted for the retrospective chart review, written consent for telephone follow-up had been obtained from all subjects.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors of the manuscript have read and agreed to its content for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"76"}}